F10 and urinary bladder carcinoma: To assess if reduced FX binding with ICVB-1042 in vitro translates to improved tolerability following IV administration, Nude mice bearing subcutaneous SW780 human bladder carcinomas were treated IV with high dose levels of ICVB-1042, ICVB-1042wt-hexon, or vehicle control on days 0, 3, and 6 (2E10 PFU per dose).